Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 285,411 shares of the specialty pharmaceutical company's stock after purchasing an additional 14,566 shares during the period. Principal Financial Group Inc. owned about 0.52% of Supernus Pharmaceuticals worth $8,899,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Commonwealth Equity Services LLC grew its holdings in Supernus Pharmaceuticals by 3.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock worth $273,000 after acquiring an additional 350 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after acquiring an additional 352 shares in the last quarter. Covestor Ltd grew its holdings in Supernus Pharmaceuticals by 15.3% during the 1st quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company's stock worth $92,000 after acquiring an additional 358 shares in the last quarter. GAMMA Investing LLC grew its holdings in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 398 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its holdings in Supernus Pharmaceuticals by 2.2% during the 2nd quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company's stock worth $741,000 after acquiring an additional 600 shares in the last quarter.

Wall Street Analyst Weigh In

SUPN has been the topic of several recent research reports. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares of the company's stock, valued at $303,236. This trade represents a 64.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jack A. Khattar sold 125,000 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. The trade was a 11.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock valued at $5,660,180 in the last three months. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Trading Up 0.4 %

Shares of NASDAQ:SUPN traded up $0.15 during trading on Tuesday, reaching $35.40. The stock had a trading volume of 60,496 shares, compared to its average volume of 448,183. The company has a market capitalization of $1.95 billion, a P/E ratio of 32.94 and a beta of 0.86. The firm's 50-day simple moving average is $33.38 and its 200 day simple moving average is $30.96. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals's revenue was up 14.2% on a year-over-year basis. During the same period last year, the firm posted ($0.29) EPS. Equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.